Standard curve
Example of Human IL-17A standard curve in Assay Diluent #1.
Product Details
Product Details
Product Specification
Antigen | IL-17A |
Immunogen | Recombinant Protein |
Antibody Type | Recombinant mAb |
Reactivity | Hu |
Purification | Protein A |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Kit
Precision | Intra-assay:4.2%; Inter-assay: 8.7% |
Sample type | Cell culture supernatant, Serum,Plasma |
Assay type | Sandwich (quantitative) |
Sensitivity | 0.880 pg/ml |
Range | 3.9 pg/mL – 250 pg/mL |
Recovery | Cell culture supernatant: 99% Serum: 84% Plasma: 106% |
Assay time | 60 minutes |
Species reactivity | Human |
NIBSC convert | The dose response curve of the International Standard (01/420) parallels the OneStep standard curve. To convert sample values obtained with the kit to approximate NIBSC (01/420) units, use the following equation: NIBSC (01/420) approximate value (IU/mL) = 0.01 x OneStep Human IL-17A value (pg/mL). |
Background
Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.
Picture
Picture
ELISA
Standard curve
Example of Human IL-17A standard curve in Assay Diluent #12R3.
Linearity
The concentrations of IL-17A were measured and interpolated from the target standard curves and corrected for sample dilution.
The sample is undiluted samples are as follows: human PBMC cells stimulated with 10ug/ml PHA for 5days (100%). The interpolated dilution factor corrected values are plotted. The mean target concentration was determined to be 68.9 pg/mL in stimulated human PBMC supernatant.
To assess the linearity of the assay, the samples were spiked with high concentrations of Human IL-17A in various matrices and diluted with the appropriate Calibrator Diluent to produce samples with values within the dynamic range of the assay.
To assess the linearity of the assay, two samples were spiked with high concentrations of Human IL-17A in various matrices and diluted with the appropriate Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Leading Competitor comparison
Protocol Diagram
